Compare Altria Group Inc (MO) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs TransMedics Group Inc — how do they compare? Altria Group Inc trades at $73.48 (market cap $124.67B), while TransMedics Group Inc trades at $73.5 (market cap $2.54B). The key difference: Altria Group Inc is far larger — about 49.1× TransMedics Group Inc's market cap, and Altria Group Inc pays a 5.68% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| MO | TMDX | |
|---|---|---|
Market Cap | $124.67B | $2.54B |
Sector | Consumer Staples | Technology |
52-Week High | $74.66 | $150.42 |
52-Week Low | $54.72 | $61.99 |
Enterprise Value | $145.75B | $2.94B |
Dividend Yield | 5.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Altria Group (MO) trades at $72.99, down 1.64% on the day, with a P/E of 15.59 and strong net income margin of 39.52%. Recent earnings show mixed results, beating estimates in Q1 2026 but missing in Q4 2025. Technical indicators suggest a bullish trend with support at $73 and resistance at $75. The company maintains robust cash flow from operations at $9.29B and declared a $1.06 dividend payable in July 2026.
MO offers a high dividend yield and stable cash flows, appealing for income investors, but faces risks from declining smoking trends and regulatory pressures. Analyst consensus is bullish with a $71 price target, though revenue stagnation and debt levels warrant caution. The stock's defensive qualities provide stability amid market volatility.
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
